Tyrosine kinase inhibitor combination therapy in first-line treatment of non-small-cell lung cancer: systematic review and network meta-analysis

References

• Paz-AresLSoulieresDMelezinekIClinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysisJ Cell Mol Med2010141–2516920015198
   PubMed Web of Science ®Google Scholar
• EllisPMCoakleyNFeldRKuruvillaSUngYCUse of the epidermal growth factor receptor inhibitors gefitinib, erlotinib, afatinib, dacomitinib, and icotinib in the treatment of non-small-cell lung cancer: a systematic reviewCurr Oncol2015223e183e21526089730
   PubMedGoogle Scholar
• National Comprehensive Cancer Network (NCCN)NCCN Clincal Practice Guidelines in Oncology (NCCN Guidelines®): Non-Small Cell Lung Cancer. Version 3.20152015 Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.aspAccessed February 1, 2017
   Google Scholar
• NovelloSBarlesiFCalifanoRMetastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnn Oncol201627suppl 5v1v2727664245
   PubMed Web of Science ®Google Scholar
• RosellRCarcerenyEGervaisRErlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialLancet Oncol201213323924622285168
   PubMed Web of Science ®Google Scholar
• WuYZhouCWuGQuality of life (QOL) analysis from ensure, a phase 3, open-label study of first-line erlotinib versus gemcitabine/cisplatin (GP) in Asian patients with epidermal growth factor receptor (EGFR) mutation-positive (MUT+) non-small-cell lung cancer (NSCLC)J Thorac Oncol201494 suppl 1S37
   Google Scholar
• MitsudomiTMoritaSYatabeYGefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trialLancet Oncol201011212112820022809
   PubMed Web of Science ®Google Scholar
• WuYLZhouCLiamCKFirst-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study+Ann Oncol20152691883188926105600
   PubMed Web of Science ®Google Scholar
• MaemondoMInoueAKobayashiKGefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFRN Engl J Med2010362252380238820573926
   PubMed Web of Science ®Google Scholar
• ZhouCWuYLChenGErlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyLancet Oncol201112873574221783417
   PubMed Web of Science ®Google Scholar
• ChenGFengJZhouCQuality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC)Ann Oncol20132461615162223456778
   PubMed Web of Science ®Google Scholar
• WuYLZhouCHuCPAfatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trialLancet Oncol201415221322224439929
   PubMed Web of Science ®Google Scholar
• GeaterSLXuCRZhouCSymptom and quality of life improvement in LUX-lung 6: an open-label Phase III study of afatinib versus cisplatin/gemcitabine in Asian patients with EGFR mutation-positive advanced non-small-cell lung cancerJ Thorac Oncol201510688388925933111
   PubMed Web of Science ®Google Scholar
• SequistLVYangJCHYamamotoNPhase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutationsJ Clin Oncol201331273327333423816960
   PubMed Web of Science ®Google Scholar
• YangJCHHirshVSchulerMSymptom control and quality of life in lux-lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutationsJ Clin Oncol201331273342335023816967
   PubMed Web of Science ®Google Scholar
• ParkKTanEHO’ByrneKAfatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trialLancet Oncol201617557758927083334
   PubMed Web of Science ®Google Scholar
• LeonLFGolsorkhiALiuSDrozdowskyARosellROverall survival analyses of first-line erlotinib versus chemotherapy in the EURTAC study population controlling for the use of post-study therapyAnn Oncol201425suppl 4iv447iv448
   Google Scholar
• JannePAYangJCKimDWAZD9291 in EGFR inhibitor-resistant non-small-cell lung cancerN Engl J Med2015372181689169925923549
   PubMed Web of Science ®Google Scholar
• SetoTKatoTNishioMErlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 studyLancet Oncol201415111236124425175099
   PubMed Web of Science ®Google Scholar
• NaumovGNNilssonMBCasconeTCombined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistanceClin Cancer Res200915103484349419447865
   PubMed Web of Science ®Google Scholar
• BurottoMManasanchEEWilkersonJFojoTGefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trialsOncologist201520440041025795635
   PubMed Web of Science ®Google Scholar
• HaalandBTanPSde CastroGJrLopesGMeta-analysis of first-line therapies in advanced non-small-cell lung cancer harboring EGFR-activating mutationsJ Thorac Oncol20149680581124787964
   PubMed Web of Science ®Google Scholar
• HaspingerERAgustoniFTorriVIs there evidence for different effects among EGFR-TKIs? Systematic review and meta-analysis of EGFR tyrosine kinase inhibitors (TKIs) versus chemotherapy as first-line treatment for patients harboring EGFR mutationsCrit Rev Oncol Hematol201594221322725523487
   PubMed Web of Science ®Google Scholar
• LeeCKBrownCGrallaRJImpact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysisJ Natl Cancer Inst2013105959560523594426
   PubMed Web of Science ®Google Scholar
• LiangWWuXFangWNetwork meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutationsPLoS One201492e8524524533047
   PubMed Web of Science ®Google Scholar
• PopatSMokTYangJCAfatinib in the treatment of EGFR mutation-positive NSCLC – a network meta-analysisLung Cancer201485223023824929780
   PubMed Web of Science ®Google Scholar
• KuanFCKuoLTChenMCOverall survival benefits of first-line EGFR tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung cancers: a systematic review and meta-analysisBr J Cancer2015113101519152826461059
   PubMed Web of Science ®Google Scholar
• MoherDLiberatiATetzlaffJAltmanDGGroupPPreferred reporting items for systematic reviews and meta-analyses: the PRISMA statementBMJ2009339b253519622551
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE)Single technology appraisal: User guide for company evidence submission template2015 Available at: https://www.nice.org.uk/process/pmg24/chapter/instructions-for-companiesAccessed February 1, 2017
   Google Scholar
• GuyotPAdesAEOuwensMJWeltonNJEnhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curvesBMC Med Res Methodol201212922297116
   PubMed Web of Science ®Google Scholar
• StataCorp Stata Statistical Software: Release 14College Station, TXStataCorp LP2015
   Google Scholar
• LunnDJacksonCBestNThomasASpiegelhalterDThe BUGS Book A Practical Introduction to Bayesian AnalysisBoca Raton, FLCRC Press2013
   Google Scholar
• SalantiGAdesAEIoannidisJPGraphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorialJ Clin Epidemiol201164216317120688472
   PubMed Web of Science ®Google Scholar
• DiasSWeltonNJSuttonAJValdwellDMGuobingLAdesAENICE DSU Technical Support Document 4: Inconsistency in Networks of Evidence Based on Randomised Controlled Trials2011 Available from: www.nicedsu.org.ukAccessed February 1, 2017
   Google Scholar
• YoshiokaHMitsudomiTMoritaSFinal overall survival results of WJTOG 3405, a randomized phase 3 trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer (NSCLC) harboring mutations of the epidermal growth factor receptor (EGFR)J Clin Oncol2014325sabstr8117
   Google Scholar
• InoueAKobayashiKMaemondoMUpdated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)Ann Oncol2013241545922967997
   PubMed Web of Science ®Google Scholar
• ZhouCWuYLChenGFinal overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)Ann Oncol20152691877188326141208
   PubMed Web of Science ®Google Scholar
• YangJWuYLSchulerMAfatinib vs cisplatin-based chemotherapy for EGFR mut positive lung adenocarcinoma (LUX-lung 3 and LUX-Lung 6): analysis of OS data from two randomized phase 3 trialsLancet Oncol201516214115125589191
   PubMed Web of Science ®Google Scholar
• ShiSBTangXYTianJChangCXLiPQiJLEfficacy of erlotinib plus dendritic cells and cytokine-induced killer cells in maintenance therapy of advanced non-small cell lung cancerJ Immunother201437425025524714359
   PubMed Web of Science ®Google Scholar
• SugawaraSOizumiSMinatoKRandomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902Ann Oncol201526588889425669832
   PubMed Web of Science ®Google Scholar
• HosomiYSetoTNishioMErlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced non-squamous non-small-cell lung cancer (NSCLC) with activating EGFR mutation (mt): JO25567 exploratory subgroup analysisAnn Oncol201526ix127ix147
   Google Scholar
• de MarinisFVergnenegreAPassaroAErlotinib-associated rash in patients with EGFR mutation-positive non-small-cell lung cancer treated in the EURTAC trialFuture Oncol201511342142925675123
   PubMedGoogle Scholar
• SooRAKawaguchiTLohMDifferences in outcome and toxicity between Asian and Caucasian patients with lung cancer treated with systemic therapyFuture Oncol20128445146222515448
   PubMed Web of Science ®Google Scholar
• HerbstRSAnsariRBustinFEfficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trialLancet201137797801846185421621716
   PubMed Web of Science ®Google Scholar
• NihoSKunitohHNokiharaHRandomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancerLung Cancer201276336236722244743
   PubMed Web of Science ®Google Scholar
• TelfordCJonesNLivingsCBatsonSNetwork meta-analysis comparing overall survival for fulvestrant 500 mg versus alternative therapies for treatment of postmenopausal, estrogen receptor-positive advanced breast cancer following failure on prior endocrine therapyClin Breast Cancer201616318819526971303
   PubMedGoogle Scholar
• European Medicines AgencyAssessment Report Avastin2016 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000582/WC500210677.pdfAccessed September 9, 2016
   Google Scholar
• MaemondoMFukuharaTSugawaraSNEJ026: phase III study comparing bevacizumab plus erlotinib to erlotinib in patients with untreated NSCLC harboring activating EGFR mutationsAnn Oncol201627suppl 6 Abstract1286Ti
   PubMedGoogle Scholar